Long-term Follow-up After Conversion from Intravenous Epoprostenol to Oral Therapy With Bosentan or Sildenafil in 13 Patients With Pulmonary Arterial Hypertension

Journal of Heart and Lung Transplantation

Volumn 26, Issue 4, 2007, Pages 363-369

  Johnson, Roger F ^a   Loyd, James E ^a   Mullican, Amy L ^a   Fink, Cynthia A ^a   Robbins, Ivan M ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; BOSENTAN; ILOPROST; PROSTACYCLIN; SILDENAFIL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DETERIORATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDICATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HEART CATHETERIZATION; HUMAN; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; MALE; MONITORING; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RISK ASSESSMENT; SURVIVAL; TERATOGENICITY; TREATMENT OUTCOME; WALKING; WEANING;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; EPOPROSTENOL; FEMALE; FOLLOW-UP STUDIES; HEART CATHETERIZATION; HUMANS; HYPERTENSION, PULMONARY; ILOPROST; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PIPERAZINES; PURINES; RETREATMENT; RETROSPECTIVE STUDIES; SULFONAMIDES; SULFONES; VASCULAR RESISTANCE; VASODILATOR AGENTS;

EID: 33947614172     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2007.01.022     Document Type: Article

References (27)

1. Badesch D.B., Tapson V.F., McGoon M.D., et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. Ann Intern Med 132 (2000) 425-434
2. Robbins I.M., Gaine S.P., Schilz R., Tapson V.F., Rubin L.J., and Loyd J.E. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. Chest 117 (2000) 14-18
3. Rosenzweig E.B., Kerstein D., and Barst R.J. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 99 (1999) 1858-1865
4. McLaughlin V.V., Genthner D.E., Panella M.M., Hess D.M., and Rich S. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. Ann Intern Med 130 (1999) 740-743
5. Aguilar R.V., and Harrison W.F. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am J Respir Crit Care Med 162 (2000) 1846-1850
6. Barst R.J., Rubin L.J., McGoon M.D., Caldwell E.J., Long W.A., and Levy P.S. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 121 (1994) 409-415
7. Barst R.J., Rubin L.J., Long W.A., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 334 (1996) 296-301
8. McLaughlin V.V., Genthner D.E., Panella M.M., and Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 338 (1998) 273-277
9. Sitbon O., Humbert M., Nunes H., et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension. J Am Coll Cardiol 40 (2002) 780-788
10. McLaughlin V.V., Shillington A., and Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 106 (2002) 1477-1482
11. Kuhn K.P., Byrne D.W., Arbogast P.G., Doyle T.P., Loyd J.E., and Robbins I.M. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med 167 (2003) 580-586
12. Robbins I.M., Cuiper L.L., Stein C.M., et al. Angiotensin II mediates systemic rebound hypertension after cessation of prostacyclin infusion in sheep. J Appl Physiol 85 (1998) 731-737
13. Rubin L.J. Primary pulmonary hypertension. N Engl J Med 336 (1997) 111-117
14. Channick R.N., Simonneau G., Sitbon O., et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358 (2001) 1119-1123
15. Rubin L.J., Badesch D.B., Barst R.J., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346 (2002) 896-903
16. Humpl T., Reyes J.T., Holtby H., Stephens D., and Adatia I. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single drug, open-label, pilot study. Circulation 111 (2005) 3274-3280
17. Bhatia S., Frantz R.P., Severson C.J., Durst L.A., and McGoon M.D. Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy. Mayo Clin Proc 78 (2003) 1207-1213
18. Michelakis E.D., McMurtry M.S., Sonnenberg B., and Archer S.L. The NO - K+ channel axis in pulmonary arterial hypertension. Activation by experimental oral therapies. Adv Exp Med Biol 543 (2003) 293-322
19. Olschewski H., Simonneau G., Galie N., et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347 (2002) 322-329
20. Galie N., Torbicki A., Barst R., et al., The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. Eur Heart J 25 (2004) 2243-2278
21. Kim N.H., Channick R.N., and Rubin L.J. Successful withdrawal of long-term epoprostenol therapy for pulmonary arterial hypertension. Chest 124 (2003) 1612-1615
22. Ivy D.D., Doran A., Claussen L., Bingaman D., and Yetman A. Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan. Am J Cardiol 93 (2004) 943-946
23. Suleman N., and Frost A.E. Transition from epoprostenol and treprostinil to the oral endothelin receptor antagonist bosentan in patients with pulmonary hypertension. Chest 126 (2004) 808-815
24. Frost A.E., Quinones M.A., Zoghbi W.A., et al. Reversal of pulmonary hypertension and subsequent repair of atrial septal defect after treatment with continuous intravenous epoprostenol. J Heart Lung Transplant 24 (2005) 501-503
25. Fruhwald F.M., Kjellstrom B., Perthold W., Wonisch M., Maier R., and Klein W. Hemodynamic observations in two pulmonary hypertensive patients changing treatment from inhaled iloprost to the oral endothelin-antagonist bosentan. J Heart Lung Transplant 24 (2005) 631-634
26. Sitbon O., Humbert M., Jais X., et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111 (2005) 3105-3111
27. Petkov V., Ziesche R., Mosgoeller W., et al. Aerosolized iloprost improves pulmonary haemodynamics in patients with primary pulmonary hypertension receiving continuous epoprostenol treatment. Thorax 56 (2001) 734-736